AUSTRALIAN Pharmaceutical Industries will stock the full range of product made by ASX-listed natural medicines and cosmetics company Bod Australia, under a new distribution agreement which makes the items available nationally.
The entire Bod range, including Pinpoint, Flexofytol and new products SediStress and Enterofytol, will be stocked by API and have now been classed as part of API's 'core range' which allows for better market positioning, improved working capital management and centralised deliveries, Bod Australia said.
New pack sizes will help secure additional 'on shelf' presence, and Bod will work with API to promote the range across Priceline, Chemsave and Pharmacy 4 Less.
The additions to API's stable will be live by mid Apr, with the exception of SediStress which should be added in Jul this year.
Bod also has plans to develop a range of products based on GMP-certified cannabis extracts.
The above article was sent to subscribers in Pharmacy Daily's issue from 06 Apr 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 06 Apr 18
